137 related articles for article (PubMed ID: 33113571)
21. Apalutamide-induced lichenoid reaction in a patient with non-metastatic castrate-resistant prostate cancer.
Cremante M; Puglisi S; Gandini A; Guadagno A; Catalano F; Damassi A; Murianni V; Llaja Obispo MA; Banna GL; Buti S; Rebuzzi SE; Rescigno P; Fornarini G
J Oncol Pharm Pract; 2023 Oct; 29(7):1748-1753. PubMed ID: 37282554
[TBL] [Abstract][Full Text] [Related]
22. Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study.
López-Abad A; Ramírez Backhaus M; Server Gómez G; Cao Avellaneda E; Moreno Alarcón C; López Cubillana P; Yago Giménez P; de Pablos Rodríguez P; Juan Fita MJ; Climent Durán MÁ; Guardiola Ruiz I; Vidal Crespo N; Artés Artés M; Montoya Chinchilla R; Moreno Avilés J; Guzmán Martínez-Valls PL; López González PÁ
Prostate Int; 2024 Mar; 12(1):20-26. PubMed ID: 38523897
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial.
Yang D; Chen W; Lai F; Qiu M; Li J
Front Oncol; 2023; 13():1110807. PubMed ID: 38023146
[TBL] [Abstract][Full Text] [Related]
24. Real-world analysis of apalutamide-associated skin rash in Chinese patients with prostate cancer.
Yang Z; Shao Y; Huang H; Liu Y; Wang Z; Wang Y
World J Urol; 2024 Mar; 42(1):171. PubMed ID: 38506974
[TBL] [Abstract][Full Text] [Related]
25. [Cost-Effectiveness Analysis and Budget Impact Analysis of Enzalutamide for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer].
Asakawa K; Idehara K; Saito A; Mitomi T; Igarashi A
Hinyokika Kiyo; 2023 Dec; 69(12):337-361. PubMed ID: 38197234
[TBL] [Abstract][Full Text] [Related]
26. CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy.
Qi Z; Bai X; Wu L; Zhang P; Guo Z; Yu Y
J Transl Med; 2024 Jun; 22(1):538. PubMed ID: 38844946
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of apalutamide with high-volume mHSPC: Real-world experience from three cases.
Jiang J; Ding H; Shang P; Wang Z
Asian J Surg; 2023 Sep; 46(9):3879-3880. PubMed ID: 37088652
[No Abstract] [Full Text] [Related]
28. Application of the ASCO value framework to evaluate the clinical and economic value of enzalutamide and apalutamide in the early stages of prostate cancer in Colombia.
Romero M; Díaz A; Sánchez K; Amaya S; Godoy F; Rodríguez D
Ecancermedicalscience; 2023; 17():1614. PubMed ID: 38414970
[TBL] [Abstract][Full Text] [Related]
29. Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
Schweizer MT; True L; Gulati R; Zhao Y; Ellis W; Schade G; Montgomery B; Goyal S; Nega K; Hakansson AK; Liu Y; Davicioni E; Pienta K; Nelson PS; Lin D; Wright J
J Urol; 2023 Feb; 209(2):354-363. PubMed ID: 36621991
[TBL] [Abstract][Full Text] [Related]
30. A practical guide for the use of apalutamide for non-metastatic castration-resistant prostate cancer in Australia.
Marx G; Chowdhury S; Krieger L; Hovey E; Shapiro J; Tran B; Tan TH; Ng S; Woo HH
Asia Pac J Clin Oncol; 2024 Apr; ():. PubMed ID: 38639402
[TBL] [Abstract][Full Text] [Related]
31. Real-world study: Impact of multidisciplinary management of apalutamide-associated adverse events in prostate cancer.
Córdoba Sánchez J; Monge-Escartín I; Gil J; Carrera C; Sáez-Peñataro J; Ferrer L; Aversa C; Mellado B; Mases J; Ribal MJ; Alcaraz A; Vilaseca A
Prostate; 2024 Jun; ():. PubMed ID: 38888199
[TBL] [Abstract][Full Text] [Related]
32. Disease-related complications in patients with metastatic hormone-sensitive prostate cancer.
Ng CF; Mak CWH; Chan SYS; Li ML; Leung CH; Teoh JYC; Chiu PKF; Chu PSK
Hong Kong Med J; 2023 Aug; 29(4):324-329. PubMed ID: 37424071
[TBL] [Abstract][Full Text] [Related]
33. TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment.
van Elst T; van Basten JP; van den Berg P; van den Bergh R; Bloem S; van Dodewaard-de Jong J; Hendriks M; Klaver S; Lalmahomed Z; Luijendijk D; van de Luijtgaarden A; Roelofs L; Vis AN; Vreugdenhil G; Vrijhof E; Wijsman B; Bloemendal H; Mulders P; Mehra N
BMJ Open; 2023 Aug; 13(8):e072572. PubMed ID: 37643855
[TBL] [Abstract][Full Text] [Related]
34. Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment.
Hamid AA; Sayegh N; Tombal B; Hussain M; Sweeney CJ; Graff JN; Agarwal N
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390166. PubMed ID: 37220335
[TBL] [Abstract][Full Text] [Related]
35. Apalutamide-associated skin rash in patients with prostate cancer: Histological evaluation by skin biopsy.
Tohi Y; Kataoka K; Miyai Y; Kaku Y; Dainichi T; Haba R; Tsunemori H; Sugimoto M
IJU Case Rep; 2021 Sep; 4(5):299-302. PubMed ID: 34497989
[TBL] [Abstract][Full Text] [Related]
36. Hypothyroidism caused by apalutamide.
Daviduck Q; North S; Swaleh R
CMAJ; 2023 Oct; 195(42):E1443. PubMed ID: 37903525
[No Abstract] [Full Text] [Related]
37. Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
Pollock Y; Smith MR; Saad F; Chowdhury S; Oudard S; Hadaschik B; Olmos D; Lee JY; Uemura H; Bhaumik A; Londhe A; Rooney B; Brookman-May SD; De Porre P; Mundle SD; Small EJ
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):813. PubMed ID: 37620428
[No Abstract] [Full Text] [Related]
38. Interstitial Lung Disease Caused by Apalutamide for Metastatic Castration-Sensitive Prostate Cancer.
Del Castillo-Acuña R; Serradilla A; López-Campos F; Couñago F
Arch Bronconeumol; 2024 Apr; ():. PubMed ID: 38705808
[No Abstract] [Full Text] [Related]
39. Is It Premature to Accept Radiographic Progression-Free Survival as a Surrogate End Point in Metastatic Hormone-Sensitive Prostate Cancer?
Garcia JA; Spratt DE
J Clin Oncol; 2024 Jun; ():JCO2400210. PubMed ID: 38875508
[No Abstract] [Full Text] [Related]
40. [Not Available].
Daviduck Q; North S; Swaleh R
CMAJ; 2024 Feb; 196(7):E242. PubMed ID: 38408780
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
